Inclusion Criteria:

          -  Signed informed consent

          -  Adult

          -  Relapsed or refractory Multiple Myeloma as defined by the IMWG

          -  Life expectancy ≥3 months

          -  ECOG performance status 0 or 1

          -  Adequate vital organ function

          -  Adequate bone marrow function

          -  Toxicities from prior/ongoing therapies recovered to ≤ Grade 2 or subject's baseline

          -  WCBP and men who can father children must be willing and able to use adequate
             contraception

        Exclusion Criteria:

          -  Any uncontrolled medical or psychiatric disorder that would preclude participation as
             outlined

          -  Pregnant or lactating women

          -  Amyloidosis

          -  Uncontrolled infection(s)

          -  Active CNS disease

          -  Previous allogeneic-HSCT

          -  History of another primary malignancy that requires intervention beyond surveillance
             or that has not been in remission for at least 1 year.

          -  Subjects that received experimental or systemic therapy < 14 days before TEG002
             infusion

          -  NYHA Class ≥ II

          -  Patients depending on dialysis

          -  Patients with a history of pulmonary embolism or deep vein thrombosis

          -  T cell mediated active autoimmune disease OR any active autoimmune disease requiring
             immunosuppressive therapy